Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 196

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy: Increase in visceral fat secondary to androgen deprivation therapy

Open access
Hamilton, E. J., Gianatti, E., Strauss, B. J., Wentworth, J., Lim-Joon, D., Bolton, D., Zajac, J. D., Grossmann, M.·2011·Clinical Endocrinology
DOI 10.1111/j.1365-2265.2010.03942.x
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Androgen deprivation therapy (ADT) for prostate cancer is associated with increases in fat mass and risk of type 2 diabetes; however, the relationship between sex steroid deficiency and abdominal fat distribution remains controversial. DESIGN: We conducted a 12-month prospective observational study at a tertiary referral centre. PATIENTS AND MEASUREMENTS: We investigated changes in abdominal fat distribution and insulin resistance in 26 men (70.6±6.8 years) with nonmetastatic prostate cancer during the first year of ADT. RESULTS: Twelve months of ADT increased visceral abdominal fat area by 22% (from 160.8±61.7 to 195.9±69.7 cm(2) ; P<0.01) and subcutaneous abdominal fat area by 13% (from 240.7±107.5 to 271.3±92.8 cm(2) ; P<0.01). Fat mass increased by 14% (+3.4 kg; P<0.001) and lean tissue mass decreased by 3.6% (-1·9 kg; P<0.001). Insulin resistance (HOMA-IR) increased by 12% (2.50±1.12 to 2.79±1.31, P<0.05). There was no change in fasting glucose or glycated haemoglobin levels. Total testosterone (TT) was inversely associated with visceral fat area independent of oestradiol (E2), but E2 was not associated with visceral fat area independent of TT. Visceral fat area, not TT or E2, was independently associated with insulin resistance. CONCLUSIONS: ADT for prostate cancer results in accumulation of both visceral and subcutaneous abdominal fat. Increased visceral fat area appears more closely linked to testosterone than oestradiol deficiency. Increased insulin resistance may arise secondary to visceral fat accumulation, rather than as a direct result of sex steroid deficiency.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2265.2010.03942.x

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 24

  1. Smith, 2007, Androgen deprivation therapy for prostate cancer: new concepts and concerns, Current Opinion in Endocrinology, Diabetes, and Obesity, 14, 247, 10.1097/MED.0b013e32814db88c · DOI
  2. Basaria, 2008, Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth, Journal of Andrology, 29, 534, 10.2164/jandrol.108.005454 · DOI
  3. Grossmann, 2010, Bone and Metabolic Health in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy-Management Guidelines on behalf of the Endocrine Society of Australia, the Australian and New Zealand Bone and Mineral Society, and the Urological Society of Australia and New Zealand, Medical Journal of Australia
  4. Shahinian, 2005, Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma, Cancer, 103, 1615, 10.1002/cncr.20955 · DOI · Paper page
  5. Lu-Yao, 2004, Changing patterns in competing causes of death in men with prostate cancer: a population based study, Journal of Urology, 171, 2285, 10.1097/01.ju.0000127740.96006.1a · DOI
  6. Smith, 2001, The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer, Journal of Clinical Endocrinology and Metabolism, 86, 4261, 10.1210/jc.86.9.4261 · doi:10.1210/jc.86.9.4261 · Paper page
  7. Basaria, 2002, Long-term effects of androgen deprivation therapy in prostate cancer patients, Clinical Endocrinology, 56, 779, 10.1046/j.1365-2265.2002.01551.x · DOI · Paper page
  8. Shahani, 2008, Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis, Journal of Clinical Endocrinology and Metabolism, 93, 2042, 10.1210/jc.2007-2595 · DOI · Paper page
  9. Ronti, 2006, The endocrine function of adipose tissue: an update, Clinical Endocrinology, 64, 355, 10.1111/j.1365-2265.2006.02474.x · DOI · Paper page
  10. Schroeder, 2004, Effects of androgen therapy on adipose tissue and metabolism in older men, Journal of Clinical Endocrinology and Metabolism, 89, 4863, 10.1210/jc.2004-0784 · DOI
  11. Hamilton, 2010, Structural Decay of Bone Microarchitecture in Men with Prostate Cancer treated with Androgen Deprivation Therapy, Journal of Clinical Endocrinology and Metabolism, 95, E456, 10.1210/jc.2010-0902 · DOI
  12. Wentworth, 2010, Pro-inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin resistance in human obesity, Diabetes, 59, 1648, 10.2337/db09-0287 · DOI · Paper page
  13. Team, 2007, R: A Language and Environment for Statistical Computing
  14. Levine, 2010, Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology, Circulation, 121, 833, 10.1161/CIRCULATIONAHA.109.192695 · DOI · Paper page
  15. Sato, 2003, Late onset of obesity in male androgen receptor-deficient (AR KO) mice, Biochemical and Biophysical Research Communications, 300, 167, 10.1016/S0006-291X(02)02774-2 · DOI · Paper page
  16. Tsai, 2004, Association of bioavailable, free, and total testosterone with insulin resistance: influence of sex hormone-binding globulin and body fat, Diabetes Care, 27, 861, 10.2337/diacare.27.4.861 · DOI · Paper page
  17. Bojesen, 2006, The metabolic syndrome is frequent in Klinefelter’s syndrome and is associated with abdominal obesity and hypogonadism, Diabetes Care, 29, 1591, 10.2337/dc06-0145 · DOI · Paper page
  18. Khaw, 1992, Lower endogenous androgens predict central adiposity in men, Annals of Epidemiology, 2, 675, 10.1016/1047-2797(92)90012-F · DOI · Paper page
  19. Tsai, 2000, Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men, International Journal of Obesity and Related Metabolic Disorders, 24, 485, 10.1038/sj.ijo.0801183 · DOI · Paper page
  20. Bottner, 2004, Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels, Journal of Clinical Endocrinology and Metabolism, 89, 4053, 10.1210/jc.2004-0303 · DOI · Paper page
  21. Lanfranco, 2004, Serum adiponectin levels in hypogonadal men: influence of testosterone replacement therapy, Clinical Endocrinology, 60, 500, 10.1111/j.1365-2265.2004.02007.x · DOI · Paper page
  22. Kapoor, 2007, The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes, European Journal of Endocrinology, 156, 595, 10.1530/EJE-06-0737 · DOI · Paper page
  23. Smith, 2008, Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome, Cancer, 112, 2188, 10.1002/cncr.23440 · DOI · Paper page
  24. Dandona, 2005, Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation, Circulation, 111, 1448, 10.1161/01.CIR.0000158483.13093.9D · DOI · Paper page

Cited by

See all 196

Metadata

Authors
Hamilton, E. J., Gianatti, E., Strauss, B. J., Wentworth, J., Lim-Joon, D., Bolton, D., Zajac, J. D., & Grossmann, M.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2011-02-08
Volume
74
Issue
3
Pages
377-383
ISSN
0300-0664 (ISSN-L)
DOI
10.1111/j.1365-2265.2010.03942.x
OpenAlex
W2107786108
Cited by
196
References
15
FWCI
7.27
Type
journal article
Language
en
Open access
bronze
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1666 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy: Increase in visceral fat secondary to androgen deprivation therapy. https://app.cochat.ai/papers/10.1111/j.1365-2265.2010.03942.x
The paper
Hamilton, E. J., Gianatti, E., Strauss, B. J., Wentworth, J., Lim-Joon, D., Bolton, D., Zajac, J. D., & Grossmann, M. (2011). Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy: Increase in visceral fat secondary to androgen deprivation therapy. Clinical Endocrinology. https://doi.org/10.1111/j.1365-2265.2010.03942.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.